The combination of venetoclax, atezolizumab, and obinutuzumab elicited responses and prolonged time progression, in patients with chronic lymphocytic leukemia with Richter transformation, according to data from the phase 2 MOLTO trial.
Research from Italy indicates that terminology used in validated questionnaires for patient-reported outcomes should account for the social and cultural contexts of the countries involved.